Differential expression of Kisspeptin in patients with and without endometriosis
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
This study investigated the expression levels of Kisspeptin in patients with and without endometriosis to identify potential differences.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- New developments in the medical treatment of endometriosis 2017
- Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy 2017
- Serum kisspeptin levels in deep-infiltrating, ovarian, and superficial endometriosis: A prospective observational study 2022
- Use of Dienogest or Gonadotropin Releasing Hormone Agonist with Add back Hormone Therapy in Longterm Endometriosis Medical Management 2018
Cited by (4)
- Serum kisspeptin levels in deep-infiltrating, ovarian, and superficial endometriosis: A prospective observational study 2022
- Use of Dienogest or Gonadotropin Releasing Hormone Agonist with Add back Hormone Therapy in Longterm Endometriosis Medical Management 2018
- New developments in the medical treatment of endometriosis 2017
- Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy 2017
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK